PMID- 25077441
OWN - NLM
STAT- MEDLINE
DCOM- 20141104
LR  - 20211021
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Print)
IS  - 0007-0920 (Linking)
VI  - 111
IP  - 6
DP  - 2014 Sep 9
TI  - HLA and KIR genotyping correlates with relapse after T-cell-replete 
      haploidentical transplantation in chronic myeloid leukaemia patients.
PG  - 1080-8
LID - 10.1038/bjc.2014.423 [doi]
AB  - BACKGROUND: Conflicting results have been reported regarding the predicative 
      roles of alloreactive natural killer (NK) cells on the outcomes of 
      transplantation in leukaemia patients. METHODS: We prospectively analysed the 
      human leukocyte antigen (HLA) typing of donor-recipient pairs and the KIR typing 
      of the donors in 97 CML patients to address the predictive roles of NK cells in 
      relapse undergoing T-cell-replete haploidentical transplantation. RESULTS: 
      Patients with class I ligands for the donor-inhibitory KIR gene exhibited 
      decreased molecular and haematologic relapse rates (P=0.003 and P=0.015, 
      respectively). There was a significantly reduced risk of molecular and 
      haematologic relapse in patients with HLA-C1C2 or C2C2 who accepted donors with 
      KIR2DS1 or in patients with HLA-Bw4 who accepted donors with KIR3DS1 ('recipient 
      with relevant KIR ligand for donor-activating KIR', n=25), compared with the 
      remaining transplants (n=72, P=0.009 and P=0.009, respectively). In addition, the 
      presence of class I ligand in the recipients of donor-activating KIR contributed 
      to a decreased relapse rate in patients lacking class I ligand in the recipient 
      of donor-inhibitory KIR (P=0.04 and P=0.03, respectively). CONCLUSIONS: This 
      study suggests that the presence of class I ligands for the donor-activating or 
      donor-inhibitory KIR gene in the recipient might confer some protection against 
      leukaemic relapse in T-cell-replete haploidentical transplantation.
FAU - Zhao, X-Y
AU  - Zhao XY
AD  - Peking University People's Hospital and Peking University Institute of 
      Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, 
      Beijing 100044, China.
FAU - Chang, Y-J
AU  - Chang YJ
AD  - Peking University People's Hospital and Peking University Institute of 
      Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, 
      Beijing 100044, China.
FAU - Xu, L-P
AU  - Xu LP
AD  - Peking University People's Hospital and Peking University Institute of 
      Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, 
      Beijing 100044, China.
FAU - Zhang, X-H
AU  - Zhang XH
AD  - Peking University People's Hospital and Peking University Institute of 
      Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, 
      Beijing 100044, China.
FAU - Liu, K-Y
AU  - Liu KY
AD  - Peking University People's Hospital and Peking University Institute of 
      Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, 
      Beijing 100044, China.
FAU - Li, D
AU  - Li D
AD  - Peking University People's Hospital and Peking University Institute of 
      Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, 
      Beijing 100044, China.
FAU - Huang, X-J
AU  - Huang XJ
AD  - 1] Peking University People's Hospital and Peking University Institute of 
      Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, 
      Beijing 100044, China [2] Peking-Tsinghua Center for Life Sciences, Beijing 
      100871, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140731
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-Bw4 antigen)
RN  - 0 (HLA-C Antigens)
RN  - 0 (HLA-C*01:02 antigen)
RN  - 0 (HLA-C*02 antigen)
RN  - 0 (KIR2DS1 protein, human)
RN  - 0 (Ligands)
RN  - 0 (Receptors, KIR)
RN  - 0 (Receptors, KIR3DS1)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Disease-Free Survival
MH  - Donor Selection
MH  - Female
MH  - Genotype
MH  - Graft vs Host Disease/etiology
MH  - HLA-B Antigens/*genetics
MH  - HLA-C Antigens/*genetics
MH  - Haploidy
MH  - Humans
MH  - Killer Cells, Natural/immunology
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics/*therapy
MH  - Ligands
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Receptors, KIR/*genetics
MH  - Receptors, KIR3DS1/*genetics
MH  - Recurrence
MH  - Survival Rate
MH  - T-Lymphocytes/*transplantation
MH  - Young Adult
PMC - PMC4453853
EDAT- 2014/08/01 06:00
MHDA- 2014/11/05 06:00
PMCR- 2015/09/09
CRDT- 2014/08/01 06:00
PHST- 2014/04/08 00:00 [received]
PHST- 2014/06/24 00:00 [revised]
PHST- 2014/07/07 00:00 [accepted]
PHST- 2014/08/01 06:00 [entrez]
PHST- 2014/08/01 06:00 [pubmed]
PHST- 2014/11/05 06:00 [medline]
PHST- 2015/09/09 00:00 [pmc-release]
AID - bjc2014423 [pii]
AID - 10.1038/bjc.2014.423 [doi]
PST - ppublish
SO  - Br J Cancer. 2014 Sep 9;111(6):1080-8. doi: 10.1038/bjc.2014.423. Epub 2014 Jul 
      31.